Nodular Sclerosis Classical Hodgkin Lymphoma

The company’s ultra-sensitive biomarker technology supports milestone achievement in establishing a method for clinicians to identify and interpret elevated values of sNfL in children and adolescents BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that its Simoa® technology supported a large international study to establish sNfL reference ranges to assess neurological disease activity in children and adolescents, according to a recent study published in The Lancet Neurology. Researchers from the University Hospital Basel and University of Basel, led by Professor Jens Kuhle, leveraged Simoa’s ability to precisely detect the sNfL protein at ultra-low levels, enabling a large-scale international study in which sNfL could be reliably measured across a spectrum of healthy persons ranging in age from neonatal to adolescence. The Blood Neurofilament Light Chain (NfL) is an innovative biomarker that specifically indicates neuroaxonal health. However, its clinical application has been constrained due to the lack of established reference ranges for children and adolescents. Accurate monitoring of neuroaxonal injury in neurologic and systemic diseases is of pivotal importance at population and individual patient levels. In the pediatric population, tools capturing neuroaxonal injury with high specificity would substantially facilitate early and accurate detection of conditions associated with short- and long-term neurological disabilities with considerable socioeconomic impact. This may also accelerate clinical trials evaluating the expanding library of targeted causal and disease-modifying treatments. “By utilizing Simoa’s ultra-sensitive technology, our research team has been able to reach this milestone achievement for two major cohorts of children and adolescents in Europe and North America,” said Jens Kuhle, Professor and Head of the Neuroimmunology Unit and Multiple Sclerosis Center at the University Hospital Basel. “Measurement of serum NfL concentrations has the potential to substantially contribute to counseling of children and their parents and adolescents with neurological conditions, representing a significant driver of pediatric disability concerns worldwide. The European Medicines Agency has recently called introducing age-adjusted reference values for NfL a top research priority in this context.” The study, “Serum neurofilament light chain reference database for individual application in pediatric care,” is the most comprehensive study within this population to date, examining 2,667 samples from donors spanning different ages, an important factor known to affect sNfL values. Persons with neurological conditions were excluded from the reference range cohorts. Because of the diverse patient set, this study helped establish a statistically robust reference database, which can be used in conjunction with a new internet-based method to support clinicians when interpreting results of sNfL levels in individual children and adolescents aged 18 years old or younger. Establishing normative values for sNfL for pediatric cases provides a vital advance to overcome some of the existing constraints, paving the way for the clinical application of blood NfL in this population. “sNfL measurements represent an important opportunity to advance the care of children with neurological conditions,” said Masoud Toloue, CEO at Quanterix. “Age-adjusted reference ranges for children expands the utility of blood NfL measurements to this population group and enables physicians to interpret what is ‘normal’ and ‘abnormal’ NfL in a quantitative and individual way in this age group for the first time. A particular advantage of the high sensitivity of the digital Simoa NfL assay is the ability to precisely measure NfL from small sample volumes, such as heel sticks from neonatal children, or even from dried blood spots. This allows a single platform to be used for all types of patients and sample types.” “With the recent addition of NfL to our expanding menu of CLIA-validated lab developed tests, we are aiming our ground-breaking Simoa technology at neurological diseases across a large spectrum of patients, including children. For example, recent data suggest sNfL may be a suitable biomarker for disease activity in children with spinal muscular atrophy in the initial stages of the disease during early childhood. The clinical potential and impact of blood NfL continues to expand, both as a single assay and in combination with other biomarkers, and we look forward to further growing our menu of clinically validated Simoa assays toward improving clinical care,” continued Toloue. To learn more about Quanterix’s Simoa® technology, visit: . For more information about Quanterix’s work in neurology, visit: . The Study Led by Jens Kuhle at the University Hospital of Basel and Sven Wellmann at the University Hospital of Regensburg, an international team comprising top-tier institutes from Switzerland, Germany, and the United States conducted comprehensive analyses of NfL concentrations in more than 2,500 healthy children and adolescents. This important study has been published in The Lancet Neurology. The study authored by A Abdelhak, F Petermeier and P Benkert et al., provides essential insights for the correct interpretation of NfL concentrations in the pediatric population, emphasizing its unique, age-related dynamics. These findings are particularly distinct from previous descriptions by the same group for the adult population. This landmark research significantly enhances the precision of pediatric health assessments and diagnoses, thereby contributing to the evolution of global children's healthcare. The established reference dataset provides healthcare providers with a definitive standard for comparison, enabling more accurate interpretation of NfL levels in children's blood tests. In turn, this facilitates more precise diagnoses, optimizes monitoring of disease progression, and enables a more individualized approach to treatment. With this key reference range, the ability to understand and monitor children's neuroaxonal health is significantly enhanced. About Quanterix From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Green light from HAS to facilitate reimbursement of METAglut1TM test in France Decision paves the way for adoption and reimbursement of the test in Europe and the U.S. PARIS--(BUSINESS WIRE)-- METAFORA biosystems, today announces that the Haute Autorité de Santé (HAS), the French Health Technology Agency, has issued a recommendation for insurance coverage of METAglut1TM, a test for the early diagnosis of De Vivo disease (or GLUT1 deficiency syndrome), a rare neurometabolic disorder. The HAS conducted a thorough evaluation of METAglut1TM, which included an assessment of its clinical performance and clinical utility. The evaluation concluded that METAglut1 is a valuable addition to the diagnostic arsenal for Glut1 DS, and was ascribed a high clinical added value. Vincent Petit, CEO of Metafora, said, “We are extremely proud to obtain HAS approval for METAglut1, a true milestone for the company and our partners, and not least for GLUT1 deficient patients. This rare neurometabolic disease is highly underdiagnosed, and we expect that METAglut1’s availability will increase awareness and help physicians to diagnose the disease earlier. We are grateful for the Forfait Innovation of the French Ministry of Health, which has allowed us to bring a multi-year prospective study to its successful conclusion. We look forward to making METAglut1 available to patients and clinicians in France and other large European countries, while we are actively exploring ways to launch the test in the U.S. as well.” Principal Investigator Prof. Fanny Mochel, Head of the Reference Centre for Adult Neurometabolic Diseases at AP-HP Pitié-Salpêtrière Hospital said, “METAglut1 quickly and accurately diagnoses GLUT1 deficiency syndrome. Its reimbursement will be of major benefit to physicians, pediatricians and neurologists, but especially to patients with this rare disease, as its early diagnosis is essential for targeted therapeutic management that can significantly improve the symptoms and daily lives of patients and their families.” About De Vivo disease & METAglut1TM – diagnose to cure De Vivo disease, or GLUT1 deficiency syndrome, is a rare and debilitating neurological disease. An estimated 30,000 people suffer from the GLUT1 deficiency syndrome in Europe and the USA, of which less than 2,000 are currently diagnosed. GLUT1-deficient patients suffer from an impaired glucose uptake by brain cells, leading to epileptic seizures, ataxia and often developmental delay. Uniquely, unlike for many genetic diseases, treatment is relatively straightforward, requiring a high-fat diet (known as a ketogenic diet), which significantly improves symptoms in patients. Early diagnosis is therefore of the essence. A multicenter validation study supported by the French Society of Neuropediatrics (SFNP) and the French Society for the Study of Innate Metabolic Diseases (SFEIM), was presented at the 3rd European GLUT1D Conference in 2021 and is accepted for a forthcoming publication in a leading scientific journal. It demonstrated that METAglut1 resulted in almost 100% specificity and a sensitivity of approximately 80%. METAglut1 identifies affected children and adults within 48 hours, unlike current diagnostic tests which rely on a lumbar puncture, an invasive procedure, and complex genetic analysis. METAglut1 is the result of a collaboration between METAFORA biosystems, the teams at Greater Paris University Hospitals (AP-HP), over 30 clinical trial sites, Cerba HealthCare, a clinical testing laboratory responsible for supporting the rollout of METAglut1 in France, and CNRS. METAglut1 is the first product to receive a recommendation through the Forfait Innovation program supported by the French Ministry of Solidarity and Health. The Forfait Innovation was critical in supporting a 30-month study in over 60 pediatric and adult neurology centers in France to demonstrate the efficacy of METAglut1 for the early detection of the GLUT1 deficiency syndrome. About METAFORA biosystems Metafora biosystems is a health-tech company based in Paris with 30 employees, developing a single-cell analysis platform. This platform allows to measure changes in single-cell metabolism, and determine “cell metabolic fitness” or lack thereof, which is a telltale sign of disease, especially in neurology, cancer and inflammatory diseases. METAglut1 is a first diagnostic test for the early diagnosis of De Vivo disease, a rare pediatric neurometabolic disorder. The company has forged key partnerships, notably with Sebia, a leading player in in vitro diagnostics, for the development of new diagnostic tests in oncology, and of a solution to increase the clinical efficacy of cell therapies and reduce manufacturing costs. Metafora has also developed METAflowTM, a cytometry data analysis software with unmatched robustness and a user-friendly interface that yields objective, reproducible, and actionable results from the increasingly large and unwieldy data sets generated by conventional, mass or spectral cytometry. A first research use only version will be launched by mid-2023, and developments are ongoing to turn METAflow into a clinical grade solution. Metafora has received grants to develop its technology platform from Bpifrance and funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 806038, and is laureate of the EIC Accelerator program from the European Commission. View source version on businesswire.com: Contacts For further information: Vincent Petit, CEO Phone: +33 6 76 71 61 14 Email: vincent.petit@metafora-biosystems.com Source: METAFORA biosystems View this news release online at:

Launch in Europe & U.S. for limited number of RUO licensees Global launch expected later in spring PARIS & CHICAGO--(BUSINESS WIRE)-- METAFORA biosystems, today announces the launch of METAflow, its digital flow cytometry platform, into the RUO market. METAflow offers the power of a highly advanced unsupervised algorithm suite through a simple, elegant workflow accessible to any user, from beginners to advanced users. A cloud-based software enabling automated multidimensional clustering of flow cytometry data, METAflow marks a dramatic advance over existing, suboptimal solutions, regardless of data processing skills. Vincent Petit, CEO of Metafora, said, “Scientists and biologists today analyze flow cytometry data either manually, through a so-called gating strategy, or through a mix of manual data preprocessing and the implementation of a series of algorithms. Multiple trial and error runs are required before finding the right settings, and getting relevant results. In contrast, METAflow offers a faster, more robust and intuitive way to reach the desired populations. We look forward to rolling out METAflow to at first a limited number of RUO licensees, and setting the stage for accessing the research community at large later this spring.” Starting today, a limited number of licensees from Europe and the U.S. will start working with METAflow. The feedback of these first customers will serve to prepare for the global roll-out of METAflow in spring, while simultaneously scaling the support team of application and digital specialists and the opening a U.S. office. About METAflow METAflow is a flow cytometry data analysis software with unmatched robustness and a seamless, comprehensive, user-friendly interface. Metafora believes that METAflow will allow hundreds of thousands of flow cytometrists to move from cumbersome sequential manual gating to automated multidimensional clustering to obtain more objective data in a much shorter timeframe. METAflow provides objective, reproducible, traceable results, all in a collaborative digital platform that empowers users to mine and retrieve the best from increasing data sets generated by conventional, mass or spectral cytometry. After a successful features’ showcase during CYTO22 and ESSCA conferences, and a year of continuous development through an early access program, METAflow is now ready to enter the RUO market. To go beyond the RUO market, Metafora is developing, partly financed through the EIC Accelerator Program, a clinical grade version for use in clinical research and in routine settings. About Metafora METAFORA biosystems has developed METAflow, a flow cytometry data analysis software with unmatched robustness and a user-friendly interface that yields objective, reproducible, and actionable results from the increasingly large and unwieldy data sets generated by conventional, mass or spectral cytometry. METAflow in combination with Metafora’s proprietary reagents underpins METAbolism, the company’s IVD activity. METAglut1 is a first diagnostic test for the early diagnosis of De Vivo disease, a rare pediatric neurometabolic disorder. The company is developing a number of oncology diagnostics as well as a solution to increase the clinical efficacy of cell therapies and reduce manufacturing costs.